Active, not recruitingPhase 2NCT05557591
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Studying Paraneoplastic cerebellar degeneration
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- BNT116(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- The Oncology Institute of Hope and Innovation, Los Angeles, California, United States
- UCLA Medical Center, Santa Monica, California, United States
- Norton Cancer Institute, Downtown, Louisville, Kentucky, United States
- San Juan Oncology Associates, Farmington, New Mexico, United States
- Weill Cornell Medicine, New York, New York, United States
- FirstHealth of the Carolinas Outpatient Cancer Center, Pinehurst, North Carolina, United States
- Millenium Research & Clinical Development, Houston, Texas, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
- LTD High Technology Hospital Medcenter, Batumi, Georgia
- LLC Todua Clinic, Tbilisi, Georgia
- LTD New Hospitals, Tbilisi, Georgia
- LTD Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi, Georgia
- LTD Cancer Research Centre, Tbilisi, Georgia
- Caucasus Medical Centre, Tbilisi, Georgia
- +15 more locations on ClinicalTrials.gov
Collaborators
BioNTech SE
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05557591 on ClinicalTrials.govOther trials for Paraneoplastic cerebellar degeneration
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07144280A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Pfizer
- RECRUITINGNCT06965166Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal CancerMayo Clinic
- RECRUITINGNANCT06080841Curcumin Supplementation in Cervical CancerNational Institute of Cancerología
- ACTIVE NOT RECRUITINGPHASE1NCT05338775A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC